Carlos Lara, MD
Family Medicine · Ocala, FLNPI 1265475511
Payments from drug & device makers
Across 151 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$424
- AbbVie$298
- AstraZeneca$297
- GSK$271
- Boehringer Ingelheim$230
- Amgen$200
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,914100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 21 | $424 |
| AbbVie(2 entities) | 19 | $298 |
| AstraZeneca | 16 | $297 |
| GSK | 10 | $271 |
| Boehringer Ingelheim | 10 | $230 |
| Amgen(2 entities) | 13 | $200 |
| Novo Nordisk | 12 | $190 |
| Watermark Medical, Inc. | 1 | $187 |
| Pfizer | 9 | $167 |
| Novartis | 8 | $119 |
| Amarin Pharma, Inc. | 4 | $67 |
| Bayer | 4 | $61 |
| Grifols USA, LLC | 2 | $49 |
| Dexcom, Inc. | 3 | $44 |
| Lilly USA, LLC | 3 | $39 |
| Abbott | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Boston Scientific | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Averitas Pharma Inc. | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SHINGRIX$125
How this compares
$2,925 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $111,805 |
| JardianceEmpagliflozin | 82 | $99,931 |
| FarxigaDapagliflozin Propanediol | 85 | $81,419 |
| JanuviaSitagliptin Phosphate | 73 | $74,726 |
| OzempicSemaglutide | 43 | $68,672 |
| TrulicityDulaglutide | 28 | $37,346 |
| XareltoRivaroxaban | 16 | $23,415 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $23,384 |
| EntrestoSacubitril/Valsartan | 16 | $15,889 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $15,075 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 116 | $14,440 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 127 | $14,179 |
| TradjentaLinagliptin | 11 | $13,553 |
| MyrbetriqMirabegron | 16 | $12,911 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $9,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $230 | $120,829107 claims |
| PfizerEliquis | $167 | $111,80591 claims |
| AstraZenecaFarxiga, Symbicort | $297 | $91,230118 claims |
| MerckJanuvia, Janumet Xr | $16 | $89,80085 claims |
| Novo NordiskOzempic | $190 | $68,67243 claims |
| Lilly USA, LLCTrulicity | $39 | $37,34628 claims |
| GSKTrelegy Ellipta | $271 | $23,38422 claims |
| NovartisEntresto | $119 | $15,88916 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $12,91116 claims |
| Sanofi-aventis U.S. LLCLantus | $424 | $7,08540 claims |
| AbbVieSynthroid | $298 | $2,69530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Ocala
- John NardandreaOcala$30.8M
- David OliverOcala$4.5M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.